
### ü´Å Pulmonary Medicine: COPD Bronchodilator Therapy

#### ‚úÖ True Statements
1. The most appropriate initial treatment strategy in **chronic obstructive pulmonary disease (COPD)** is determined by **disease severity** and **exacerbation history**.
2. Patients with **COPD in Global Initiative for Chronic Obstructive Lung Disease (GOLD) group B** should be treated with **combination inhaled long-acting Œ≤2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) bronchodilator therapy**.
3. Patients with **COPD in GOLD group A** should be treated with a **short- or long-acting bronchodilator** (Œ≤2-agonist or muscarinic antagonist).
4. In **GOLD group A COPD**, a **long-acting bronchodilator** is preferred unless symptoms are very mild, in which case a **short-acting agent** may be used as needed.
5. An **as-needed short-acting Œ≤2-agonist (SABA)**, such as **albuterol alone**, is **inadequate therapy** for patients with **GOLD group B COPD**.
6. Patients with **COPD in GOLD group E** should be treated with **combination LABA and LAMA therapy** and can be considered for the **addition of an inhaled glucocorticoid**.
7. The combination of a **LABA and an inhaled glucocorticoid** is **not a preferred regimen in COPD**.
8. **Roflumilast** is a selective **phosphodiesterase-4 inhibitor** that can be added to bronchodilators in patients with **severe COPD and chronic bronchitis** to **reduce exacerbation frequency**.
9. **Roflumilast** is not indicated in patients with COPD who are **not receiving bronchodilator therapy** and who have **no recent exacerbations**.

#### üí¨ Extra
2. Example agents include **salmeterol (LABA)** and **tiotropium (LAMA)**.
6. Inhaled glucocorticoids in COPD are mainly reserved for patients with **frequent exacerbations** and **eosinophilic inflammation**.
7. Unlike in asthma, inhaled glucocorticoids are **not used as monotherapy** in COPD.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #BronchodilatorTherapy #LABA #LAMA #GOLDGuidelines #AmbulatoryCare

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease*. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üÜî Question ID
PMMCQ24051

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, Management of COPD, Pharmacologic Therapy for COPD, Bronchodilators

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Bronchodilators
1. **Inhaled bronchodilators** for **COPD** include **Œ≤2-agonists** and **anticholinergic/antimuscarinic agents**.
2. Both **short-acting Œ≤2-agonists (SABAs)** and **short-acting muscarinic antagonists** produce **similar bronchodilation** and can be used as **monotherapy** in COPD.
3. **Dual therapy** with a **short-acting Œ≤2-agonist and a short-acting muscarinic antagonist** results in **greater bronchodilation and expiratory airflow** than either alone, which may provide **additional symptom benefit**.
4. If symptoms in COPD are **not controlled with short-acting bronchodilators**, a **long-acting bronchodilator (LABA or LAMA)** should be added.
5. Selection of a **long-acting bronchodilator** in COPD depends on **patient preference, physician preference, potential adverse effects, and cost**.
6. If COPD symptoms persist on **long-acting bronchodilator monotherapy**, addition of a **second long-acting bronchodilator from the alternate class** may improve clinical outcomes.
7. **Long-acting bronchodilators alone** should **not be used in patients with a history or diagnosis of asthma** unless an **inhaled glucocorticoid** is also prescribed.
8. Use of a **LABA without an inhaled glucocorticoid** in patients with **asthma** carries a **potential increased mortality risk**.

#### üí¨ Extra
7‚Äì8. The mortality risk comes from asthma-specific studies showing adverse outcomes when LABAs were used without inhaled glucocorticoids.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #Bronchodilators #SABA #LABA #LAMA #AntimuscarinicAgents #AsthmaOverlap

---

#### üóæ Supplemental Tables

<!-- Table 1: GOLD Patient Category -->
<table>
  <caption><strong>Classification of COPD Severity by GOLD Patient Category</strong></caption>
  <thead>
    <tr>
      <th>Patient Category</th>
      <th>Characteristics</th>
      <th>Exacerbations Per Year</th>
      <th>CAT Score</th>
      <th>mMRC Score</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>Low risk, fewer symptoms</td>
      <td>&le;1, no hospitalization</td>
      <td>&lt;10</td>
      <td>0&ndash;1</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Low risk, more symptoms</td>
      <td>&le;1, no hospitalization</td>
      <td>&ge;10</td>
      <td>&ge;2</td>
    </tr>
    <tr>
      <td>E</td>
      <td>High risk</td>
      <td>&ge;2 or &ge;1 with hospitalization</td>
      <td>Any</td>
      <td>Any</td>
    </tr>
  </tbody>
</table>
<p><em>CAT = COPD Assessment Test; GOLD = Global Initiative for Chronic Obstructive Lung Disease; mMRC = Modified Medical Research Council dyspnea scale.</em></p>
<p><em>Information from Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.</em></p>

#### ‚úÖ True Statements (from Table: Classification of COPD Severity by GOLD Patient Category)
1. The **GOLD assessment** assigns patients to **category A, B, or E** based on **symptom burden** and **exacerbation history**.
2. **Category A** is defined by **CAT score &lt;10 or modified Medical Research Council (mMRC) score 0‚Äì1** and **&le;1 exacerbation/year without hospitalization**.
3. **Category B** is defined by **CAT score &ge;10 or mMRC score &ge;2** and **&le;1 exacerbation/year without hospitalization**.
4. **Category E** is defined by **&ge;2 exacerbations/year** or **&ge;1 exacerbation requiring hospitalization**, with **any CAT or mMRC score**.

<!-- Table 2: mMRC -->
<table>
  <caption><strong>Modified Medical Research Council Dyspnea Scale</strong></caption>
  <thead>
    <tr>
      <th>Score</th>
      <th>Description of Dyspnea</th>
      <th>Severity</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>0</td>
      <td>I only get breathless with strenuous exercise.</td>
      <td>None</td>
    </tr>
    <tr>
      <td>1</td>
      <td>I get short of breath when hurrying on level ground or walking up a slight hill.</td>
      <td>Mild</td>
    </tr>
    <tr>
      <td>2</td>
      <td>I walk slower than people of the same age on level ground because of breathlessness, or I have to stop for breath when walking at my own pace on level ground.</td>
      <td>Moderate</td>
    </tr>
    <tr>
      <td>3</td>
      <td>I stop for breath after walking approximately 100 m or after a few minutes on level ground.</td>
      <td>Severe</td>
    </tr>
    <tr>
      <td>4</td>
      <td>I am too breathless to leave the house or I am breathless when dressing or undressing.</td>
      <td>Very severe</td>
    </tr>
  </tbody>
</table>
<p><em>Adapted from Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2:257. PMID: 13823475.</em></p>

#### ‚úÖ True Statements (from Table: Modified Medical Research Council Dyspnea Scale)
1. An **mMRC score of 0** corresponds to **breathlessness only with strenuous exercise**.
2. An **mMRC score of 1** corresponds to **dyspnea when hurrying on level ground or walking up a slight hill**.
3. An **mMRC score of 2** corresponds to **walking slower than age-matched peers due to breathlessness** or **needing to stop for breath when walking at one‚Äôs own pace on level ground**.
4. An **mMRC score of 3** corresponds to **stopping for breath after ~100 meters or a few minutes on level ground**.
5. An **mMRC score of 4** corresponds to being **too breathless to leave the house** or **breathless when dressing or undressing**.

<!-- Table 3: Pharmacologic Management by GOLD Classification -->
<table>
  <caption><strong>Recommended Pharmacologic Management of COPD by GOLD Classification</strong></caption>
  <thead>
    <tr>
      <th>Patient Group</th>
      <th>Recommended Therapy</th>
      <th>Alternative or Additional Therapy</th>
      <th>Other Considerations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>Short-acting bronchodilator <em>or</em><br>Long-acting bronchodilator</td>
      <td>Evaluate effect of therapy and continue, stop, or try alternative bronchodilator as appropriate</td>
      <td>All patients in this group should receive bronchodilator therapy based on its effect on dyspnea; therapy should be continued if symptomatic benefit is documented</td>
    </tr>
    <tr>
      <td>B</td>
      <td>LABA+LAMA</td>
      <td>If a LABA+LAMA combination is not appropriate, there is no evidence to recommend one agent over the other; choice should depend on the patient's perception of symptom relief</td>
      <td>Long-acting inhaled bronchodilators are superior to short-acting bronchodilators received as needed;<br>No evidence supports use of one class of long-acting bronchodilators over another for initial relief of symptoms in this group;<br>Patients in group B are likely to have comorbidities that affect symptoms and prognosis, and these should be investigated</td>
    </tr>
    <tr>
      <td>E</td>
      <td>LABA+LAMA<br>LABA+LAMA+ICS<sup>a</sup></td>
      <td>If exacerbations continue, consider:<br>Roflumilast (patients with an FEV1 &lt;50% of predicted and chronic bronchitis, particularly if &ge;2 exacerbations or &ge;1 hospitalization in past year)<br><em>or</em><br>Macrolide therapy (best evidence supports use of azithromycin)<br><em>or</em><br>Dupilumab (patients with chronic bronchitis)<sup>a</sup></td>
      <td>Patients with concomitant asthma should receive an ICS</td>
    </tr>
  </tbody>
</table>
<p><em>GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid (glucocorticoid); LABA = long-acting Œ≤<sub>2</sub>-agonist; LAMA = long-acting muscarinic antagonist.</em></p>
<p><em><sup>a</sup>Consider if eosinophil count &ge;300/¬µL (0.30 &times; 10<sup>9</sup>/L).</em></p>
<p><em>Information from Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.</em></p>

#### ‚úÖ True Statements (from Table: Recommended Pharmacologic Management of COPD by GOLD Classification)
1. **Group A COPD** can be treated with a **short-acting or long-acting bronchodilator**, with reassessment to **continue, stop, or switch** based on benefit.
2. In **Group B COPD**, **dual long-acting bronchodilator therapy (LABA+LAMA)** is recommended.
3. In **Group E COPD**, **LABA+LAMA** is recommended, and **LABA+LAMA+inhaled corticosteroid (ICS)** is considered when **blood eosinophils are &ge;300/¬µL**.
4. For persistent exacerbations in **Group E COPD**, **roflumilast** is considered when **FEV1 &lt;50% predicted** with **chronic bronchitis**, **macrolide therapy** (e.g., **azithromycin**) is an option, and **dupilumab** may be considered for **chronic bronchitis** when **eosinophils are elevated**.
5. Patients with **concomitant asthma** should receive an **inhaled corticosteroid** as part of their regimen.
6. In **Group B COPD**, there is **no evidence favoring one long-acting bronchodilator class over another** for initial symptom relief.